Action of Fluoroquinolones and Linezolid on Logarithmic- and Stationary-Phase Culture of <i>Mycobacterium tuberculosis</i>

Abstract

Background: The new challenges involved in the chemotherapy of tuberculosis make it necessary to find novel drugs, especially ones that are useful in the latent phase of the disease. Methods: We evaluated the activity of linezolid and fluoroquinolones against logarithmic- and stationary-phase Mycobacterium tuberculosis. Results: We observed that linezolid exhibits antibacterial action, although slowly, in both situations. Quinolones with an 8-methoxy group exhibit greater activity than levofloxacin in logarithmic growth phases, whereas levofloxacin exhibits greater activity in stationary-phase growth. Conclusion: The study of the activity of drugs against the M. tuberculosis microorganism in the latent phase is one of the most important tools available in the fight against the tuberculosis epidemic, and both linezolid and the new fluoroquinolones appear to be promising drugs.

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China

“…In the first 4-6 weeks of the intensive phase using high-dose linezolid is aimed at exerting significant bactericidal activity for mycobacteria in logarithmic growth phase. In the continuous treatment phase the purpose of low-dose linezolid is to exhibit the long-term sterilising activity against the sporadically multiplying mycobacteria in stationary-phase growth [33]. Meanwhile, therapeutic drug monitoring (TDM) might reduce dose and adverse events of linezolid in the management of the drug dosage [34].…”

Susceptibility of <i>Mycobacterium tuberculosis </i>Strains to Gatifloxacin and Moxifloxacin by Different Methods

“…Unlike the other quinolones, the absence of halide in gatifl oxacin and moxifl oxacin at C-8 position results in potent anti-mycobacterial activity. It has also been reported that both gatifl oxacin and moxifl oxacin have greater in vivo activity alone, and in combination with other anti-TB drugs, in mice [10][11][12] and demonstrated excellent early bactericidal activity in human subjects [7][8] , also under in vitro conditions [9,22] .…”

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

“…Linezolid has demonstrated high in vitro antibacterial activity against Mycobacterium tuberculosis, 8,9 and has been used to treat complicated cases of resistant TB in several programmes. [10][11][12] Given that patients with refractory and/or XDR-TB have few treatment options, linezolid may well be a useful addition to the armamentarium.…”